PT - JOURNAL ARTICLE AU - Ke, Ruian AU - Martinez, Pamela P. AU - Smith, Rebecca L. AU - Gibson, Laura L. AU - Achenbach, Chad J. AU - McFall, Sally AU - Qi, Chao AU - Jacob, Joshua AU - Dembele, Etienne AU - Bundy, Camille AU - Simons, Lacy M. AU - Ozer, Egon A. AU - Hultquist, Judd F. AU - Lorenzo-Redondo, Ramon AU - Opdycke, Anita K. AU - Hawkins, Claudia AU - Murphy, Robert L. AU - Mirza, Agha AU - Conte, Madison AU - Gallagher, Nicholas AU - Luo, Chun Huai AU - Jarrett, Junko AU - Conte, Abigail AU - Zhou, Ruifeng AU - Farjo, Mireille AU - Rendon, Gloria AU - Fields, Christopher J. AU - Wang, Leyi AU - Fredrickson, Richard AU - Baughman, Melinda E. AU - Chiu, Karen K. AU - Choi, Hannah AU - Scardina, Kevin R. AU - Owens, Alyssa N. AU - Broach, John AU - Barton, Bruce AU - Lazar, Peter AU - Robinson, Matthew L. AU - Mostafa, Heba H. AU - Manabe, Yukari C. AU - Pekosz, Andrew AU - McManus, David D. AU - Brooke, Christopher B. TI - Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution AID - 10.1101/2021.08.30.21262701 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.30.21262701 4099 - http://medrxiv.org/content/early/2021/09/02/2021.08.30.21262701.short 4100 - http://medrxiv.org/content/early/2021/09/02/2021.08.30.21262701.full AB - The global effort to vaccinate people against SARS-CoV-2 in the midst of an ongoing pandemic has raised questions about the nature of vaccine breakthrough infections and the potential for vaccinated individuals to transmit the virus. These questions have become even more urgent as new variants of concern with enhanced transmissibility, such as Delta, continue to emerge. To shed light on how vaccine breakthrough infections compare with infections in immunologically naive individuals, we examined viral dynamics and infectious virus shedding through daily longitudinal sampling in a small cohort of adults infected with SARS-CoV-2 at varying stages of vaccination. The durations of both infectious virus shedding and symptoms were significantly reduced in vaccinated individuals compared with unvaccinated individuals. We also observed that breakthrough infections are associated with strong tissue compartmentalization and are only detectable in saliva in some cases. These data indicate that vaccination shortens the duration of time of high transmission potential, minimizes symptom duration, and may restrict tissue dissemination.Competing Interest StatementCBB and LW are listed as inventors on a pending patent application for the saliva RTqPCR test used in this study.Funding StatementThis work was supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health [3U54HL143541-02S2] through the RADx-Tech program. This work was also supported by the National Institute of Biomedical Imaging and Bioengineering through the Center for Innovation in Point of Care Technologies for HIV/AIDS at Northwestern (C-THAN) [3U54EB027049-02S1]. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Institute of Biomedical Imaging and Bioengineering; the National Heart, Lung, and Blood Institute; the National Institutes of Health, or the U.S. Department of Health and Human Services.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Western Institutional Review Board, and all participants provided informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data will be made available at the time of publication in a peer-reviewed journal.